Skip to main content
HCPCS J1072 · Level II · Part B drug

J1072: testosterone cypionate (Azmiro), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1072

Billing unit
1 MG
Inj, testosterone, azmiro
ASP payment limit
$1.301
October 2026; +0.4% vs July 2026
Practitioner MUE
400
MAI 3
OPPS status
SI K
APC 2069
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS J1072 is the Level II code for Injection, testosterone cypionate (azmiro), 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $1.301 per billing unit, up 0.4% from July 2026. The practitioner MUE allows up to 400 units per date of service (MAI 3), so a full 400-unit day is $520.40 at the current limit. Under OPPS it carries status indicator K in APC 2069. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names testosterone cypionate: J1071 (the code whose CMS descriptor names no specific product). The ASP crosswalk maps 2 NDCs to it, sold as Azmiro by Azurity Pharmaceuticals, Inc. 1 Medicare coverage article lists the code across 4 states, including A58828.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1072 at $1.301 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $1.296 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1072
QuarterPayment limitPerCoinsurance
October 2026$1.3011 MG20%
July 2026$1.2961 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J1072. Report the NDC in the claim's drug segment and bill the number of J1072 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J1072
NDCDrug nameLabelerPackage sizeBilling units / package
24338-0055-01AzmiroAzurity Pharmaceuticals, Inc.1 × 1200
24338-0056-01AzmiroAzurity Pharmaceuticals, Inc.1 × 1200

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J1072. For practitioners the limit is 400 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1072 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services4003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital4003 Date of Service Edit: ClinicalPrescribing Information
DME supplier4003 Date of Service Edit: ClinicalPrescribing Information

MUE for J1072 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1072 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1072 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1072 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J1072 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J1072
ArticleTitleContractor(s)StatesRelated LCD
A58828Billing and Coding: Treatment of Males with Low TestosteronePalmetto GBANC SC VA WVL39086

Diagnoses Medicare contractors cover for J1072

One billing and coding article attaches a covered diagnosis list to J1072: 39 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J1072
ICD-10-CMDescription (FY2027)Articles covering
D35.2Benign neoplasm of pituitary gland1 of 1
D44.3Neoplasm of uncertain behavior of pituitary gland1 of 1
E23.0Hypopituitarism1 of 1
E23.1Drug-induced hypopituitarism1 of 1
E23.3Hypothalamic dysfunction, not elsewhere classified1 of 1
E23.6Other disorders of pituitary gland1 of 1
E23.7Disorder of pituitary gland, unspecified1 of 1
E29.1Testicular hypofunction1 of 1
E29.8Other testicular dysfunction1 of 1
E30.0Delayed puberty1 of 1
E89.5Postprocedural testicular hypofunction1 of 1
F64.0Transsexualism1 of 1
F64.1Dual role transvestism1 of 1
F64.2Gender identity disorder of childhood1 of 1
F64.8Other gender identity disorders1 of 1
24 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1072 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J1072, by article
ArticleContractorGroups that applyCovered codes for J1072Full list
A58828Palmetto GBAone list for every code in the article39On LCD L39086

Local coverage policies that list J1072

1 active Local Coverage Determination lists J1072 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

  • L39086 Treatment of Males with Low Testosterone · Palmetto GBA

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1072 carries status indicator K and is assigned to APC 2069, with a published national unadjusted payment of $1.301. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1072 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $1.30 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J1072 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1072

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1072

What does HCPCS code J1072 describe?

J1072 is defined by CMS as "Injection, testosterone cypionate (azmiro), 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1072 a CPT code?

No. J1072 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as testosterone cypionate (Azmiro); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1072 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1072 in October 2026?

The ASP-based payment limit is $1.301 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $1.296. Commercial payers use their own fee schedules.

How many units of J1072 can be billed per day?

The practitioner Medically Unlikely Edit is 400 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J1072?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Azmiro (Azurity Pharmaceuticals, Inc.). For example NDC 24338-0055-01 (package size 1) equals 200 billing units of J1072.

Does J1072 have NCCI bundling edits?

No active practitioner PTP pairs list J1072 as a column-1 or column-2 code in the v323r0 release.

J1072 vs J1071: what is the difference?

Both are HCPCS Level II codes whose descriptor names testosterone cypionate. What sets J1071 apart: the code whose CMS descriptor names no specific product. J1072 is billed per 1 mg, limit $1.301, MUE 400; J1071 is billed per 1 mg, limit $0.023, MUE 400. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J1072?

1 current Billing and Coding Article in the Medicare Coverage Database lists J1072, covering 4 states: A58828 (Billing and Coding: Treatment of Males with Low Testosterone).

What diagnosis codes support J1072?

One Medicare billing and coding article lists 39 covered ICD-10-CM codes for J1072, for example D35.2 (Benign neoplasm of pituitary gland); D44.3 (Neoplasm of uncertain behavior of pituitary gland); E23.0 (Hypopituitarism); E23.1 (Drug-induced hypopituitarism); E23.3 (Hypothalamic dysfunction, not elsewhere classified). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.